

Published in final edited form as:

Biochimie. 2010 June ; 92(6): 620–626. doi:10.1016/j.biochi.2010.03.001.

Localization and function of cytosolic phospholipase A₂α at the Golgi

Christina C. Leslie^{*}, Todd A. Gangelhoff, and Michael H. Gelb

Department of Pediatrics, National Jewish Health, Denver, CO 80206, USA and Departments of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195, USA

Abstract

Cytosolic phospholipase A₂α (cPLA₂α, Group IVA phospholipase A₂) is a central mediator of arachidonate release from cellular phospholipids for the biosynthesis of eicosanoids. cPLA₂α translocates to intracellular membranes including the Golgi in response to a rise in intracellular calcium level. The enzyme's calcium-dependent phospholipid-binding C2 domain provides the targeting specificity for cPLA₂α translocation to the Golgi. However, other features of cPLA₂α regulation are incompletely understood such as the role of phosphorylation of serine residues in the catalytic domain and the function of basic residues in the cPLA₂α C2 and catalytic domains that are proposed to interact with anionic phospholipids in the membrane to which cPLA₂α is targeted. Increasing evidence strongly suggests that cPLA₂α plays a role in regulating Golgi structure, tubule formation and intra-Golgi transport. For example, recent data suggests that cPLA₂α regulates the transport of tight junction and adherens junction proteins through the Golgi to cell-cell contacts in confluent endothelial cells. However, there are now examples where data based on knockdown using siRNA or pharmacological inhibition of enzymatic activity of cPLA₂α affects fundamental cellular processes yet these phenotypes are not observed in cells from cPLA₂α deficient mice. These results suggest that in some cases there may be compensation for the lack of cPLA₂α. Thus, there is continued need for studies employing highly specific cPLA₂α antagonists in addition to genetic deletion of cPLA₂α in mice.

Keywords

cytosolic phospholipase A₂; Golgi; arachidonic acid; calcium; trafficking

1. Introduction

Since the discovery of a high molecular weight, arachidonic acid preferring cytosolic phospholipase A₂ (cPLA₂), now classified as Group IVA cPLA₂ (cPLA₂α), there has been a great deal of progress in elucidating its biochemical properties, regulation and function [1–8]. The interest in cPLA₂α stems from its role as the first regulatory enzyme in the pathway for the production of oxygenated metabolites of arachidonic acid [9].

© 2010 Elsevier Masson SAS. All rights reserved.

^{*}Corresponding author. Tel.: 303-398-1214; fax: 303-270-2155. leslicc@njhealth.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Among the 20 enzymes classified as PLA₂s in mammals, cPLA₂α is the only member that exhibits preference for the *sn*-2 arachidonyl group [6,10–13]. cPLA₂α is expressed in many cell types and is highly regulated in order to control the cellular levels of free arachidonic acid. The function of cPLA₂α in mediating the regulated release of arachidonic acid for the production of eicosanoids is well established [14–18]. These potent lipid mediators have diverse functions in regulating normal processes and contributing to disease pathogenesis [9]. In cells involved in promoting acute inflammation in response to tissue injury such as neutrophils, macrophages and mast cells, cPLA₂α activation results in the production of numerous lipid mediators including leukotrienes, prostanoids and platelet-activating factor [14–18]. These mediators have diverse functions in promoting inflammation and contributing to its resolution. The coordinated action of secreted lipid mediators is regulated in a cell type specific manner by the differential expression of specific G-protein coupled receptors that initiate diverse signal transduction pathways and biological responses [19–21].

In addition to its role in initiating eicosanoid production, there is data indicating that cPLA₂α plays a role in regulating the structure and trafficking through the Golgi apparatus. Evidence is emerging that phospholipases and acyltransferases regulate trafficking and membrane tubulation by modification of the local lipid composition that affects membrane curvature [22–27]. This review will highlight new information about the localization and functional role of cPLA₂α at the Golgi.

2. Calcium-dependent translocation of cPLA₂α to the Golgi

cPLA₂α is regulated by post-translational mechanisms such as increases in levels of intracellular calcium [Ca²⁺]_i, phosphorylation and interaction of basic residues with anionic membrane components (Fig. 1) [4,5]. Agonists that increase [Ca²⁺]_i stimulate cPLA₂α-dependent release of arachidonic acid by promoting translocation of cPLA₂α from the cytosol to membrane [28–32]. This is a critical regulatory step necessary for cPLA₂α to access phospholipid substrate. The cPLA₂α C2 domain has a high affinity for calcium, which binds to anionic residues in the calcium binding loops (CBLs) [33–36]. Calcium binding reduces the negative electrostatic potential of the surface exposed CBLs allowing the surrounding hydrophobic residues in CBL1 and CBL3 to penetrate membrane (Fig. 1) [37–40]. In contrast, calcium binding to other C2 domains, such as the protein kinase C alpha (PKCα) C2 domain, induces an "electrostatic switch" from electronegative to electropositive promoting the interaction of basic residues with anionic phospholipids [41–45]. Differences in the properties of C2 domains determines the lipid binding specificity *in vitro* and the membrane targeting specificity in cells [46–50]. The cPLA₂α C2 domain preferentially binds to phosphatidylcholine (PC) and mediates the calcium-dependent translocation of cPLA₂α to the Golgi, endoplasmic reticulum and nuclear envelope (Fig. 1) [31,34,38,51,52]. The PKCα C2 domain exhibits calcium-dependent binding to anionic phospholipids and translocates to the inner leaflet of the plasma membrane, which is enriched in the negatively charged phospholipids phosphatidylserine and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) [44, 46–50].

In early studies it was observed that cPLA₂α translocates to the perinuclear region including the nuclear envelope in a variety of cells in response to increases in [Ca²⁺]_i [29,30,53]. This was particularly interesting in light of work showing localization of 5-lipoxygenase, 5-lipoxygenase activating protein and leukotriene C₄ synthase to the nuclear envelope suggesting that this may be a site for production of leukotrienes [54–56]. Subsequent work using organelle markers and Golgi disrupting agents clearly demonstrated that cPLA₂α also translocates to the Golgi apparatus, which in most cells is located adjacent to the nucleus [31]. Translocation of cPLA₂α is regulated by both the amplitude and duration of [Ca²⁺]_i. The concentration of calcium required for binding to Golgi is lower than for association with the endoplasmic

reticulum (ER)/nuclear envelope [31,32]. This is consistent with data showing that cPLA₂α preferentially translocates to the Golgi in response to physiological increases in $[Ca^{2+}]_i$ that occurs with agonists such as ATP and serum, and to Golgi and the ER/nuclear envelope in response to calcium ionophores, which cause a supra-physiological rise in $[Ca^{2+}]_i$ [31]. Serum induces a typical capacitative increase in $[Ca^{2+}]_i$ and potently stimulates arachidonic acid release. The initial transient increase in calcium from intracellular stores promotes the rapid translocation of cPLA₂α to Golgi [57]. However the subsequent influx of extracellular calcium due to store depletion is essential for stable binding of cPLA₂α to Golgi and for arachidonic acid release [57]. This is evident from results showing that chelating extracellular calcium, which blocks calcium influx but not the initial calcium transient from intracellular stores, prevents serum-stimulated arachidonic acid release. Therefore a rapid transient increase from intracellular stores in this model in itself is not sufficient for cPLA₂α to release arachidonic acid [57]. However a low amplitude sustained calcium increase due to influx of extracellular calcium that occurs in the absence of a rapid calcium transient from intracellular stores, results in a slow rate of cPLA₂α translocation to Golgi and low level arachidonic acid release [57]. Collectively, studies have established the importance of extracellular calcium influx and the duration of calcium elevation for stable binding of cPLA₂α to Golgi and arachidonic acid release [32,57–59].

3. Role of the phospholipid binding specificity in targeting cPLA₂α to Golgi

Most C2 domains are calcium-dependent phospholipid binding domains that function to promote interaction of proteins to membrane. In several cell models, cPLA₂α C2 domain has been shown to localize to the same intracellular membranes as full-length cPLA₂α in response to calcium increases indicating that it is responsible for the membrane targeting specificity [22,31,48]. Hydrophobic residues in the CBLs in the cPLA₂α C2 domain are required for calcium-dependent binding to PC rich vesicles *in vitro* and localization to intracellular membranes in cells (Fig. 1) [38,39,51,60,61]. The sites of cPLA₂α localization, Golgi, ER and nuclear envelope, are the sites for synthesis of PC [62,63]. It has been suggested that a high local concentration of PC on internal membranes functions to lower the $[Ca^{2+}]_i$ necessary for cPLA₂α C2 domain to bind to these membrane [47,48].

The enrichment of PC in intracellular membranes may be sufficient to provide the targeting specificity of cPLA₂α to internal membranes. However, the role for an additional lipid or protein in regulating cPLA₂α targeting to internal membranes cannot be ruled out. There are studies suggesting that ceramide-1-phosphate (C-1-P), produced from ceramide kinase (CERK), is an endogenous regulator of cPLA₂α that acts by enhancing calcium-dependent membrane binding and activity [64–66]. *In vitro* studies demonstrated that C-1-P acts through the cPLA₂α C2 domain to increase the calcium-dependent binding of cPLA₂α to PC-containing mixed micelles and acts as an allosteric activator by decreasing the dissociation constant [67]. C-1-P is a much better activator of cPLA₂α *in vitro* when a mixed-micelle assay consisting of PC in Triton X-100 detergent micelles is used versus PC liposomes. For example the presence of 5 mole% C-1-P in Triton X-100/PC mixed micelles leads to a ~15-fold activation of cPLA₂α [67], whereas with PC liposomes the activation is ~2-fold (M. Gelb and C. Leslie, unpublished) [65]. This is reminiscent of the activation reported by PI(4,5)P₂, where the activation is much more pronounced with mixed micelles than with liposomes [57,68]. This tends to suggest that when the PC is at low surface packing density (mixed-micelles), cPLA₂α is more dependent on anionic lipid additives for binding to membranes and activation. This creates controversy for the role of these anionic lipids in regulating the action of cPLA₂α in cells. Although a PC liposome is only a model of a cell membrane, it is arguably a better model than a PC-detergent mixed particle containing mostly Triton X-100.

The interaction of cPLA₂α with C-1-P *in vitro* is mediated in part by basic residues (R57/K58/R59) in the C2 domain, and mutations in these residues impair agonist-induced translocation of cPLA₂α (Fig. 1) [69,70]. The major route of C-1-P production is the phosphorylation of ceramide by CERK. Knockdown of CERK by siRNA results in a partial reduction in C-1-P levels and reduces agonist-induced arachidonic acid release and translocation of cPLA₂α in A549 cells [64,66]. Collectively these studies have led to the hypothesis that C-1-P produced from CERK is a proximal activator of cPLA₂α, necessary for its C2 domain-dependent membrane binding and ability to release arachidonic acid. This is an attractive hypothesis since CERK localizes to the Golgi for production of C-1-P [66,71]. However, results of recent studies do not corroborate these conclusions. Generation of CERK^{-/-} mice confirmed that CERK plays a major role in production of N-palmitoyl-C-1-P in mast cells, macrophages and cerebellum although in some cells (neutrophils) CERK is not the major pathway for C-1-P production [70,72]. However, cPLA₂α-dependent release of arachidonic acid and eicosanoid production is identical in wild type and CERK^{-/-} macrophages and kidney fibroblasts despite a greater reduction in C-1-P compared to cells treated with siRNA [70,72]. In addition, no differences are observed in wild type and CERK^{-/-} mice in a cPLA₂α-dependent model of rheumatoid arthritis [72]. Additional results using a specific CERK inhibitor suggest that the lack of effect on cPLA₂α regulation in CERK^{-/-} cells and mice is not due to compensatory mechanisms. The specific CERK inhibitor NVP-231 significantly reduces cellular levels of C-1-P but has no effect on arachidonic acid release or PGE₂ production in several cell types stimulated with a variety of agonists [73]. These results do not support a role for the CERK-dependent production of C-1-P as a generalized mechanism for regulating cPLA₂α and eicosanoid production. The results raise the question of why siRNA knockdown of CERK inhibits arachidonic acid release but this is not observed in CERK^{-/-} cells or with a specific CERK inhibitor. It also raises questions about the basis for the translocation defect observed with cPLA₂α mutated at the putative C-1-P binding site in the C2 domain [70]. It is possible that there are other components on the Golgi that bind to this site. Alternatively mutating this site may result in subtle conformational alteration of the CBLs and affect Ca²⁺-dependent translocation in cells. Clearly more studies are required to resolve the discrepancies regarding the role of CERK and C-1-P in regulating cPLA₂α.

4. Regulation of cPLA₂α activity at the Golgi

Calcium-dependent translocation of cPLA₂α positions the catalytic domain on the membrane for interaction with phospholipid substrate (Fig. 1). A comparison of the calcium-induced translocation of full-length cPLA₂α and the C2 domain to Golgi revealed that the C2 domain acts as a calcium sensor and translocates in direct proportion to [Ca²⁺]_i [74]. Translocation of full-length cPLA₂α is slightly slower but it remains associated with the Golgi in a calcium-independent fashion unlike the C2 domain, which rapidly dissociates as [Ca²⁺]_i decreases. There is little experimental data that well defines the basis of catalytic domain binding to the interface of the Golgi membrane in cells. The only clear result is that a tryptophan residue on the membrane-exposed face of the catalytic domain contributes to the prolonged calcium-independent residence of cPLA₂α at the Golgi [74].

Translocation to membrane is necessary but not sufficient for cPLA₂α to release arachidonic acid. The hydrolytic activity of cPLA₂α is independently regulated by phosphorylation and by interaction of an anionic membrane component with basic residues in the catalytic domain (Fig.1). Phosphorylation on Ser-505 has been studied most extensively since it is the site for MAPKs, a common signaling pathway that regulates the release of arachidonic acid [4,75]. cPLA₂α that is completely dephosphorylated is active when assayed *in vitro* and phosphorylation on Ser-505 modestly enhances activity by about 2-fold [57,75,76,77]. Ser-505 phosphorylation is not sufficient for cPLA₂α to release arachidonic acid but acts synergistically with increases in calcium [75,78–80]. Phosphorylation of cPLA₂α on Ser-505 has been

reported to increase the membrane binding affinity at low calcium [81]. However, wild type cPLA₂ α and cPLA₂ α Ser-505A mutant exhibit similar rates of translocation to Golgi in response to physiological agonists, but the mutant releases less arachidonic acid [57,82]. These results suggest that phosphorylation at Ser-505 enhances release of arachidonic acid but not calcium-dependent translocation, which is consistent with *in vitro* data showing that Ser-505 phosphorylation increases catalytic activity but not calcium-dependent interfacial binding [57].

The phosphorylation sites of cPLA₂ α , Ser-505 and Ser-727, are located in a flexible region that is not near either the membrane binding face or the active site (Fig. 1). This raises questions as to how phosphorylation regulates cPLA₂ α function. It has been suggested that phosphorylation of Ser-505, which is located near the interdomain flexible linker region, may promote optimal orientation of the C2 and catalytic domains for efficient catalysis [83]. Phosphorylation at Ser-505 by MAPKs is generally accompanied by phosphorylation at Ser-727, which occurs by kinases downstream of MAPK such as MAPK-interacting kinase [80,84,85]. Ser-727 phosphorylation plays a novel role in regulating the interaction of cPLA₂ α with p11 (S100A10)/annexin A2 complexes (Fig. 1) [86]. This bulky complex binds to the hydroxy group of Ser-727, which maintains cPLA₂ α in an inactive state by interfering with membrane binding *in vitro* and blocking translocation of cPLA₂ α to peri-nuclear membranes in cells (Fig. 1) [86–88]. The interaction of p11/annexin A2 complex with cPLA₂ α is prevented by phosphorylation of Ser-727 thus allowing calcium-dependent interaction of cPLA₂ α with membrane and release arachidonic acid [86].

The activity cPLA₂ α is enhanced by several types of polyphosphoinositides through interaction with a patch of basic residues (K488/K541/K543/K544) in the catalytic domain [68,89–92]. It was shown that PI(4,5)P₂ facilitates binding of cPLA₂ α to PC/Triton X-100 mixed micelles and promotes activation of cPLA₂ α in a calcium-independent manner [68,91]. However, other studies have shown that PI(4,5)P₂ in PC liposomes enhances cPLA₂ α activity in the presence but not in the absence of calcium [57,89]. This is reminiscent of studies with C-1-P described above showing that cPLA₂ α activation by the anionic additive is much more pronounced with mixed-micelles versus liposomes. *In vitro* data showing that PI(4,5)P₂ primarily acts to enhance catalytic activity and not interfacial binding is consistent with cellular data showing that wild type cPLA₂ α and the K488N/K543N/K544N mutant exhibit similar rates of translocation to Golgi in response to serum but the mutant releases less arachidonic acid (Fig. 1) [57]. In addition, it has been shown that translocation of cPLA₂ α to internal membranes induced by loading cells with PI(4,5)P₂ occurs in the presence but not in the absence of intracellular calcium [92]. Although polyphosphoinositides activate cPLA₂ α *in vitro* and when loaded into cells, further studies are needed to definitively identify the endogenous anionic component on the Golgi that activates cPLA₂ α through the basic residues in the catalytic domain.

5. Function of cPLA₂ α at the Golgi

Several studies have provided evidence that cPLA₂ α regulates the structure and function of the Golgi. The expression of cPLA₂ α in LLC-PK1 kidney epithelial cells, which are deficient in cPLA₂ α , causes disruption of the Golgi cisternae and blocks the constitutive transport of aquaporin-2 to the plasma membrane [93]. The effect on Golgi structure is suggested to be due to the ability of cPLA₂ α to generate free fatty acids and lysophospholipids that modify the properties of the Golgi membrane.

cPLA₂ α also plays a role in regulating the structure and function of the Golgi that occurs by modifying cellular cholesterol content (Fig. 1). Increasing cellular cholesterol induces vesiculation of the Golgi apparatus that occurs by a cPLA₂ α - and dynamin-dependent mechanism [94]. Loading cells with cholesterol induces the translocation of cPLA₂ α to the

Golgi and an increase in arachidonic acid release. Vesiculation of the Golgi by cholesterol is blocked by a cPLA₂α inhibitor suggesting that enzymatic production of free fatty acids and lysophospholipids are involved. Conversely it has been shown that lowering Golgi cholesterol inhibits the association of cPLA₂α with the Golgi resulting in a decrease in the release of arachidonic acid and accumulation of caveolin-1 in the Golgi [95]. The ability of a cPLA₂α inhibitor to block transport of caveolin-1 from the Golgi supports a role for cPLA₂α activity in regulating trafficking. These studies highlight the important role of membrane lipid composition in regulating the association of cPLA₂α with the Golgi and a role for cPLA₂α in regulating Golgi structure and transport.

There is considerable evidence that modification of Golgi lipid composition by phospholipases and acyltransferases influences membrane curvature and regulates tubulation and vesicle formation (Fig. 1) [22,23,96,97]. cPLA₂α has recently been shown to be required for formation of tubules that connect the Golgi stacks and for regulation of intra-Golgi transport [22]. When transport through the Golgi is activated, cPLA₂α is recruited to the rims of the Golgi cisternae and to rim-associated tubules. Similar translocation to Golgi of the cPLA₂α C2 domain during transport suggests a role for local calcium increases perhaps from the high intraluminal levels in the Golgi. cPLA₂α is also associated with the Golgi during steady state trafficking. The function of cPLA₂α is specific for regulating tubule formation and intra-Golgi trafficking but not formation of Golgi vesicles or other trafficking pathways [22]. cPLA₂α is proposed to act by generating lysophospholipids at the rims of the Golgi cisternae to promote positive membrane curvature for formation of tubules (Fig. 1).

Several studies have identified a role for cPLA₂α and its association with Golgi in regulating the function of endothelial cells. Endothelial cells line the luminal surfaces of blood vessels and serve a barrier function due to tight junctions and endothelial adherens [98]. Endothelial cells proliferate during wound healing for formation of new blood vessels and during tumor formation. The proliferation of sub-confluent human umbilical vein endothelial cells, and cell cycle entry, is blocked by the cPLA₂α inhibitor pyrrolidine-1 and siRNA knockdown of cPLA₂α [99]. It is known that sub-confluent endothelial cells release greater amounts of arachidonic acid than confluent cells [100]. The decrease in proliferation and arachidonic acid release in confluent endothelial cells correlates with a redistribution of cPLA₂α from the cytosol and nucleus to the Golgi [99]. Localization to Golgi does not require an increase in [Ca²⁺]_i and correlates with inhibition of cPLA₂α due to interaction with annexin A1 [101]. It is suggested that annexin-1 at the Golgi sequesters cPLA₂α and prevents direct interaction with Golgi membrane and association with substrate.

However, recent findings have demonstrated that localization of cPLA₂α at the Golgi in confluent endothelial plays a functional role in regulating cell-cell junction formation [102]. The translocation of cPLA₂α to the Golgi correlates with the initial maturation of adherens junctions, and disruption of junctions using a VE-cadherin blocking antibody causes cPLA₂α to dissociate from the Golgi. Results suggest that VE-cadherin clustering may provide signals for promoting translocation of cPLA₂α to the Golgi. Once on the Golgi cPLA₂α regulates the transport of junction proteins through and/or from the Golgi to cell-cell contacts, which is blocked by siRNA knockdown of cPLA₂α. Treating confluent endothelial cell with cPLA₂α inhibitors causes accumulation of proteins that form adherens junction (VE-cadherin) and tight junctions (occludin, claudin-5) in the Golgi suggesting that cPLA₂α enzymatic activity is required for transport of junction proteins [102]. Therefore although cPLA₂α localization to Golgi in confluent endothelial cells may dampen the agonist-induced release of arachidonic acid, cPLA₂α maintains a level of activity that is required for regulating Golgi trafficking. The regulation of junction formation in endothelial cells by cPLA₂α is not due to the production of prostaglandins [102]. These studies implicate a role for formation of the immediate products of cPLA₂α action, free fatty acids and lysophospholipids, or a non-

prostanoid lipid mediator, in regulating Golgi function although the actual mechanism remains to be defined.

6. The need for specific PLA₂ inhibitors

Studies presented above provide strong evidence that cPLA₂ α plays a role in regulating fundamental cellular processes such as Golgi trafficking. This raises the question of why the cPLA₂ α knockout mouse does not exhibit more profound phenotypic alterations. It is certainly possible that there is adaptation in response to the genetic ablation of cPLA₂ α in mice and compensatory pathways come into play. It is unlikely that cells would rely on a single pathway for regulating important physiological cell functions. This is illustrated in studies that clearly show a role for cPLA₂ α in regulating tubulation and intra-Golgi transport, yet these processes function normally in fibroblasts from the cPLA₂ α knockout mouse [22]. An siRNA screen to determine the role of other PLA₂s of the Group IV, VI, VII and VIII families, found that silencing of only the GVIII PLA₂ inhibited Golgi transport in cPLA₂ α -deficient fibroblasts [22]. The cPLA₂ α knockout mouse has been very useful in elucidating the role of cPLA₂ α in disease, but compensatory pathways may obscure our understanding of the full functional role of cPLA₂ α . This argues for the importance of developing specific inhibitors for mammalian PLA₂s to more accurately evaluate the role of these important enzymes in regulating normal cellular processes and in disease pathogenesis.

Probably the most reliable cPLA₂ α inhibitors for use in cellular studies are the pyrrolidines developed at Shionogi and the indoles developed at Wyeth [103,104]. These compounds inhibit cPLA₂ α in the sub-micromolar range using a number of different *in vitro* lipolysis assays and they block cPLA₂ α -dependent arachidonate release in mammalian cells in the 0.01–1 μ M range [103–107]. The pyrrolidine and indole inhibitors have recently been shown to be efficacious in mouse models showing a role for cPLA₂ α in collagen-induced arthritis and in experimental autoimmune encephalomyelitis, respectively [108,109]. They do not inhibit the human cPLA₂ β and cPLA₂ γ isoforms but data on the mouse isoforms are not yet available [105, 110]. However, recent data show that the pyrrolidines and indoles work about as well on mouse cPLA₂ ζ as on cPLA₂ α *in vitro* [111]. In fact, these compounds block arachidonate release in mouse lung fibroblasts prepared from cPLA₂ α deficient mice, suggesting that cPLA₂ ζ can contribute at least some of the arachidonate in these cells. There is no data on the effect of these inhibitors on purified human cPLA₂ ζ or on mouse and human cPLA₂ δ and cPLA₂ ϵ . The groups of Lehr and Kokotos have reported on a series of ketone-containing compounds that are also potent inhibitors of cPLA₂ α [112,113]. Studies in the author's laboratories are underway to fully explore the specificity of cPLA₂ α inhibitors on the complete set of human and mouse Group IV PLA₂ isoforms.

In summary, we have available sub-micromolar cPLA₂ α inhibitors that work in cell models, but the full reliability of these compounds must await further analysis in terms of cross-specificity with other cPLA₂ isoforms. Such inhibitors, when combined with siRNA and gene deletion, will lead to a comprehensive understanding of the function of individual members of the Group IV cPLA₂ family.

Acknowledgments

The authors acknowledge funding from the National Institutes of Health.

References

1. Alonso F, Henson PM, Leslie CC. A cytosolic phospholipase in human neutrophils that hydrolyzes arachidonoyl-containing phosphatidylcholine. *Biochim. Biophys. Acta* 1986;878:273–280. [PubMed: 3092867]

2. Leslie CC, Voelker DR, Channon JY, Wall MM, Zelarney PT. Properties and purification of an arachidonoyl-hydrolyzing phospholipase A₂ from a macrophage cell line, RAW 264.7. *Biochim. Biophys. Acta* 1988;963:476–492. [PubMed: 3143418]
3. Clark JD, Milona N, Knopf JL. Purification of a 110-kilodalton cytosolic phospholipase A₂ from the human monocytic cell line U937. *Proc. Natl. Acad. Sci. USA* 1990;87:7708–7712. [PubMed: 2217203]
4. Clark JD, Schievella AR, Nalefski EA, Lin L-L. Cytosolic phospholipase A₂. *J. Lipid Mediat. Cell Signal* 1995;12:83–117. [PubMed: 8777586]
5. Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A₂ family. *Prog. Lipid Res* 2006;45:487–510. [PubMed: 16814865]
6. Clark JD, Lin L-L, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N, Knopf JL. A novel arachidonic acid-selective cytosolic PLA₂ contains a Ca²⁺-dependent translocation domain with homology to PKC and GAP. *Cell* 1991;65:1043–1051. [PubMed: 1904318]
7. Sharp JD, White DL, Chiou XG, Goodson T, Gamboa GC, McClure D, Burgett S, Hoskins J, Skatrud PL, Sportsman JR, Becker GW, Kang LH, Roberts EF, Kramer RM. Molecular cloning and expression of human Ca²⁺-sensitive cytosolic phospholipase A₂. *J. Biol. Chem* 1991;266:14850–14853. [PubMed: 1869522]
8. Kramer RM, Roberts EF, Manetta J, Putnam JE. The Ca²⁺-sensitive cytosolic phospholipase A₂ is a 100-kDa protein in human monoblast U937 cells. *J. Biol. Chem* 1991;266:5268–5272. [PubMed: 2002059]
9. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* 2001;294:1871–1875. [PubMed: 11729303]
10. Leslie CC. Regulation of arachidonic acid availability for eicosanoid production. *Biochem. Cell Biol* 2004;82:1–17. [PubMed: 15052324]
11. Leslie CC. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A₂. *Prostagl. Leukotr. Essen. Fatty Acids* 2004;70:373–376.
12. Hanel AM, Schüttel S, Gelb MH. Processive interfacial catalysis by mammalian 85-kilodalton phospholipase A₂ enzymes on product-containing vesicles: application to the determination of substrate preferences. *Biochemistry* 1993;32:5949–5958. [PubMed: 8507635]
13. Sundler R, Winstedt D, Wijkander J. Acyl-chain selectivity of the 85 kDa phospholipase A₂ and of the release process in intact macrophages. *Biochem. J* 1994;301:455–458. [PubMed: 8042988]
14. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A₂. *Nature* 1997;390:622–625. [PubMed: 9403693]
15. Diaz BL, Fujishima H, Sapirstein A, Bonventre JV, Arm JP. Participation of cytosolic phospholipase A₂ in eicosanoid generation by mouse bone marrow-derived mast cells. *Adv. Exp. Med. Biol* 2002;507:41–46. [PubMed: 12664562]
16. Uozumi N, Kume K, Nagase T, Nakatani N, Ishii S, Tashiro F, Komagata Y, Maki K, Ikuta K, Ouchi Y, Miyazaki J, Shimizu T. Role of cytosolic phospholipase A₂ in allergic response and parturition. *Nature* 1997;390:618–622. [PubMed: 9403692]
17. Gijón MA, Spencer DM, Siddiqi AR, Bonventre JV, Leslie CC. Cytosolic phospholipase A₂ is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A₂ regulation. *J. Biol. Chem* 2000;275:20146–20156. [PubMed: 10867029]
18. Rubin BB, Downey GP, Koh A, Degousee N, Ghomashchi F, Nallan L, Stefanski E, Harkin DW, Sun C, Smart BP, Lindsay TF, Cherepanov V, Vachon E, Kelvin D, Sadilek M, Brown GE, Yaffe MB, Plumb J, Frinstein S, Glogauer M, Gelb MH. Cytosolic phospholipase A₂-α is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection. cPLA₂-α does not regulate neutrophil NADPH oxidase activity. *J. Biol. Chem* 2005;280:7519–7529. [PubMed: 15475363]
19. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. *J. Clin. Invest* 2001;108:25–30. [PubMed: 11435452]
20. Evans JF. The cysteinyl leukotriene receptors. *Prostaglandins Leukot Essent Fatty Acids* 2003;69:117–122. [PubMed: 12895594]

21. Okuno T, Yokomizo T, Hori T, Miyano M, Shimizu T. Leukotriene B₄ receptor and the function of its helix 8. *J. Biol. Chem* 2005;280:32049–32052. [PubMed: 16046389]
22. San Pietro E, Capestrano MG, Polishchuk EV, DiPentima A, Trucco A, Zizza P, mariggio S, Pulvirenti T, Sallese M, Tete S, Mironov AA, Leslie CC, Corda D, Luini A, Polishchuk RS. Group IV phospholipase A₂ controls the formation of inter-cisternal continuities involved in intra-Golgi transport. *PLoS Biol* 2009;7:e1000194. [PubMed: 19753100]
23. Schmidt JA, Brown WJ. Lysophosphatidic acid acyltransferase 3 regulates Golgi complex structure and function. *J. Cell Biol* 2009;186:211–218. [PubMed: 19635840]
24. Chernomordik LV, Kozlov MM. Protein-lipid interplay in fusion and fission of biological membranes. *Annu. Rev. Biochem* 2003;72:175–207. [PubMed: 14527322]
25. Voeltz GK, Prinz WA. Sheets, ribbons and tubules - how organelles get their shape. *Nat. Mol. Cell Biol* 2007;8:258–264.
26. Zimmerberg J, Chernomordik LV. Synaptic membranes bend to the will of a neurotoxin. *Science* 2005;310:1626–1627. [PubMed: 16339436]
27. Rigoni M, Caccin P, Gschmeissner S, Koster G, Postle AD, Rossetto O, Schiavo G, Montecucco C. Equivalent effect of snake PLA₂ neurotoxins and lysophospholipid-fatty acid mixtures. *Science* 2005;310:1678–1680. [PubMed: 16339444]
28. Channon J, Leslie CC. A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A₂ with membrane in the macrophage cell line, RAW 264.7. *J. Biol. Chem* 1990;265:5409–5413. [PubMed: 2108137]
29. Schievella AR, Regier MK, Smith WL, Lin L-L. Calcium-mediated translocation of cytosolic phospholipase A₂ to the nuclear envelope and endoplasmic reticulum. *J. Biol. Chem* 1995;270:30749–30754. [PubMed: 8530515]
30. Glover S, de Carvalho MS, Bayburt T, Jonas M, Chi E, Leslie CC, Gelb MH. Translocation of the 85-kDa phospholipase A₂ from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. *J. Biol. Chem* 1995;270:15359–15367. [PubMed: 7797525]
31. Evans JH, Spencer DM, Zweifach A, Leslie CC. Intracellular calcium signals regulating cytosolic phospholipase A₂ translocation to internal membranes. *J. Biol. Chem* 2001;276:30150–30160. [PubMed: 11375391]
32. Hirabayashi T, Kume K, Hirose K, Yokomizo T, Iino M, Itoh H, Shimizu T. Critical duration of intracellular Ca²⁺ response required for continuous translocation and activation of cytosolic phospholipase A₂. *J. Biol. Chem* 1999;274:5163–5169. [PubMed: 9988766]
33. Perisic O, Fong S, Lynch DE, Bycroft M, Williams RL. Crystal structure of a calcium-phospholipid binding domain from cytosolic phospholipase A₂. *J. Biol. Chem* 1998;273:1596–1604. [PubMed: 9430701]
34. Nalefski EA, Slazas MM, Falke JJ. Ca²⁺-signaling cycle of a membrane-docking C2 domain. *Biochemistry* 1997;36:12011–12018. [PubMed: 9340010]
35. Ball A, Nielsen R, Gelb MH, Robinson BH. Interfacial membrane docking of cytosolic phospholipase A₂ C2 domain using electrostatic potential-modulated spin relaxation magnetic resonance. *Proc. Natl. Acad. Sci. U S A* 1999;96:6637–6642. [PubMed: 10359764]
36. Xu G-Y, McDonagh T, Hsiang-Ai Y, Nalefski EA, Clark JD, Cumming DA. Solution structure and membrane interactions of the C2 domain of cytosolic phospholipase A₂. *J. Mol. Biol* 1998;280:485–500. [PubMed: 9665851]
37. Davletov B, Perisic O, Williams RL. Calcium-dependent membrane penetration is a hallmark of the C2 domain of cytosolic phospholipase A₂ whereas the C2A domain of synaptotagmin binds membranes electrostatically. *J. Biol. Chem* 1998;273:19093–19096. [PubMed: 9668093]
38. Perisic O, Paterson HF, Mosedale G, Lara-González S, Williams RL. Mapping the phospholipid-binding surface and translocation determinants of the C2 domain from cytosolic phospholipase A₂. *J. Biol. Chem* 1999;274:14979–14987. [PubMed: 10329700]
39. Bittova L, Sumandea M, Cho W. A structure-function study of the C2 domain of cytosolic phospholipase A₂. *J. Biol. Chem* 1999;274:9665–9672. [PubMed: 10092653]

40. Nalefski EA, Wisner MA, Chen JZ, Sprang SR, Fukuda M, Mikoshiba K, Falke JJ. C2 domains from different Ca^{2+} signaling pathways display functional and mechanistic diversity. *Biochemistry* 2001;40:3089–3100. [PubMed: 11258923]
41. Murray D, Honig B. Electrostatic control of the membrane targeting of C2 domains. *Molecular Cell* 2002;9:145–154. [PubMed: 11804593]
42. Verdaguer N, Corbalan-Garcia S, Ochoa WF, Fita I, Gomez-Fernandez JC. $\text{Ca}(2+)$ bridges the C2 membrane-binding domain of protein kinase C α directly to phosphatidylserine. *EMBO J* 1999;18:6329–6338. [PubMed: 10562545]
43. Nalefski EA, Newton AC. Membrane binding kinetics of protein kinase C β II mediated by the C2 domain. *Biochemistry* 2001;40:13216–13229. [PubMed: 11683630]
44. Corbalán-García S, Rodríguez-Alfaro JA, Gómez-Fernández JC. Determination of the calcium-binding sites of the C2 domain of protein kinase C α that are critical for its translocation to the plasma membrane. *Biochem. J* 1999;337:513–521. [PubMed: 9895296]
45. Kohout SC, Corbalan-Garcia S, Gomez-Fernandez JC, Falke JJ. C2 domain of protein kinase calpha: elucidation of the membrane docking surface by site-directed fluorescence and spin labeling. *Biochemistry* 2003;42:1254–1265. [PubMed: 12564928]
46. Evans JH, Gerber SH, Murray D, Leslie CC. The calcium binding loops of the cytosolic phospholipase A₂ C2 domain specify targeting to Golgi and ER in live cells. *Mol. Biol. Cell* 2004;15:371–383. [PubMed: 13679516]
47. Corbin JA, Evans JH, Landgraf KE, Falke JJ. Mechanism of specific membrane targeting by C2 domains: Localized pools of target lipid enhance Ca^{2+} affinity. *Biochemistry* 2007;46:4322–4336. [PubMed: 17367165]
48. Stahelin RV, Rafter JD, Das S, Cho W. The molecular basis of differential subcellular localization of C2 domains of protein kinase C- α and group IVA cytosolic phospholipase A₂. *J. Biol. Chem* 2003;278:12452–12460. [PubMed: 12531893]
49. Cho W, Stahelin RV. Membrane binding and subcellular targeting of C2 domains. *Biochim. Biophys. Acta* 2006;1761:838–849.
50. Evans JH, Murray D, Leslie CC, Falke JJ. Specific translocation of protein kinase C α to the plasma membrane requires both Ca^{2+} and PIP_2 recognition by its C2 domain. *Mol. Biol. Cell* 2006;17:56–66. [PubMed: 16236797]
51. Nalefski EA, McDonagh T, Somers W, Seehra J, Falke JJ, Clark JD. Independent folding and ligand specificity of the C2 calcium-dependent lipid binding domain of cytosolic phospholipase A₂. *J. Biol. Chem* 1998;273:1365–1372. [PubMed: 9430670]
52. Hixon MS, Ball A, Gelb MH. Calcium-dependent and -independent interfacial binding and catalysis of cytosolic group IV phospholipase A₂. *Biochemistry* 1998;37:8516–8526. [PubMed: 9622504]
53. Peters-Golden M, Song K, Marshall T, Brock T. Translocation of cytosolic phospholipase A₂ to the nuclear envelope elicits topographically localized phospholipid hydrolysis. *Biochem. J* 1996;318:797–803. [PubMed: 8836122]
54. Brock TG, McNish RW, Peters-Golden M. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. *J. Biol. Chem* 1995;270:21652–21658. [PubMed: 7665580]
55. Christmas P, Weber BM, McKee M, Brown D, Soberman RJ. Membrane localization and topology of leukotriene C₄ synthase. *J. Biol. Chem* 2002;277:28902–28908. [PubMed: 12023288]
56. Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibin JA, Charleson S, Singer II. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. *J. Exp. Med* 1993;178:1935–1946. [PubMed: 8245774]
57. Tucker DE, Ghosh M, Ghomashchi F, Loper R, Suram S, St. John B, Girotti M, Bollinger JG, Gelb MH, Leslie CC. Role of phosphorylation and basic residues in the catalytic domain of cytosolic phospholipase A₂ α in regulating interfacial kinetics and binding and cellular function. *J. Biol. Chem* 2009;284:9596–9611. [PubMed: 19176526]
58. Chang W-C, Parekh AB. Close functional coupling between Ca^{2+} release-activated Ca^{2+} channels, arachidonic acid release, and leukotriene C₄ secretion. *J. Biol. Chem* 2004;279:29994–29999. [PubMed: 15133023]

59. Rzigalinski BA, Blackmore PF, Rosenthal MD. Arachidonate mobilization is coupled to depletion of intracellular calcium stores and influx of extracellular calcium in differentiated U937 cells. *Biochim. Biophys. Acta* 1996;1299:342–352. [PubMed: 8597589]
60. Nalefski EA, Falke JJ. Location of the membrane-docking face on the Ca^{2+} -activated C2 domain of cytosolic phospholipase A_2 . *Biochemistry* 1998;37:17642–17650. [PubMed: 9922129]
61. Gerber SH, Rizo J, Sudhof TC. The top loops of the C2 domains from synaptotagmin and phospholipase A_2 control functional specificity. *J. Biol. Chem* 2001;276:32288–32292. [PubMed: 11447211]
62. Heneberry AL, Wright MM, McMaster CR. The major sites of cellular phospholipid synthesis and molecular determinants of fatty acid and lipid head group specificity. *Mol. Biol. Cell* 2002;13:3148–3161. [PubMed: 12221122]
63. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. *Nat. Mol. Cell Biol* 2008;9:112–124.
64. Pettus BJ, Bielawska A, Spiegel S, Roddy P, Hannun YA, Chalfant CE. Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. *J. Biol. Chem* 2003;278:38206–38213. [PubMed: 12855693]
65. Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, Freiberg EJHJ, Roddy P, Hannun YA, Chalfant CE. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A_2 . *J. Biol. Chem* 2004;279:11320–11326. [PubMed: 14676210]
66. Lamour NF, Stahelin RV, Wijesinghe DS, Maceyka M, Wang E, Allegood JC, Merrill AH, Cho W, Chalfant CE. Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis. *J. Lipid Res* 2007;48:1293–1304. [PubMed: 17392267]
67. Subramanian P, Stahelin RV, Szulc Z, Bielawska A, Chi W, Chalfant CE. Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A_2a and enhances the interaction of the enzyme with phosphatidylcholine. *J. Biol. Chem* 2005;280:17601–17607. [PubMed: 15743759]
68. Mosior M, Six DA, Dennis EA. Group IV cytosolic phospholipase A_2 binds with high affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity. *J. Biol. Chem* 1998;273:2184–2191. [PubMed: 9442060]
69. Stahelin RV, Subramanian P, Vora M, Cho W, Chalfant CE. Ceramide-1-phosphate binds group IVA cytosolic phospholipase A_2 via a novel site in the C2 domain. *J. Biol. Chem* 2007;282:20467–20474. [PubMed: 17472963]
70. Lamour NF, Subramanian P, Wijesinghe DS, Stahelin RV, Bonventre JV, Chalfant CE. Ceramide 1-phosphate is required for the translocation of Group IVA cytosolic phospholipase A_2 and prostaglandin synthesis. *J. Biol. Chem* 2009;284:26897–26907. [PubMed: 19632995]
71. Carre A, Graf C, Stora S, Mechtcheriakova D, Csonga R, Urtz N, Billich A, Baumruker T, Bornancin F. Ceramide kinase targeting and activity determined by its N-terminal pleckstrin homology domain. *Biochem. Biophys. Res. Commun* 2004;324:1215–1219. [PubMed: 15504344]
72. Graf C, Zemann B, Rovina P, Urtz N, Schanzer A, Reuschel R, Mechtcheriakova D, Muller M, Fischer EH, Reichel C, Huber S, Dawson J, Meingassner JG, Billich A, Niwa S, Badegruber R, Van Veldhoven PP, Kinzel B, Baumruker T, Bornancin F. Neutropenia with impaired immune response to *Streptococcus pneumoniae* in ceramide kinase-deficient mice. *J. Immunol* 2008;180:3457–3466. [PubMed: 18292572]
73. Graf C, Klumpp M, Habig M, Rovina P, Billich A, Baumruker T, Oberhauser B, Bornancin F. Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. *Mol. Pharmacol* 2008;74:925–932. [PubMed: 18612076]
74. Evans JH, Leslie CC. The cytosolic phospholipase A_2 catalytic domain modulates association and residence time at Golgi membranes. *J. Biol. Chem* 2004;279:6005–6016. [PubMed: 14623879]
75. Lin L-L, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA_2 is phosphorylated and activated by MAP kinase. *Cell* 1993;72:269–278. [PubMed: 8381049]
76. Bayburt T, Gelb MH. Interfacial catalysis by human 85 kDa cytosolic phospholipase A_2 on anionic vesicles in the scooting mode. *Biochemistry* 1997;36:3216–3231. [PubMed: 9115999]

77. Nemenoff RA, Winitz S, Qian N-X, Van Putten V, Johnson GL, Heasley LE. Phosphorylation and activation of a high molecular weight form of phospholipase A₂ by p42 microtubule-associated protein 2 kinase and protein kinase C. *J. Biol. Chem* 1993;268:1960–1964. [PubMed: 8380583]
78. Qiu Z-H, Gijón MA, de Carvalho MS, Spencer DM, Leslie CC. The role of calcium and phosphorylation of cytosolic phospholipase A₂ in regulating arachidonic acid release in macrophages. *J. Biol. Chem* 1998;273:8203–8211. [PubMed: 9525925]
79. Lin L-L, Lin AY, Knopf JL. Cytosolic phospholipase A₂ is coupled to hormonally regulated release of arachidonic acid. *Proc. Natl. Acad. Sci. USA* 1992;89:6147–6151. [PubMed: 1631101]
80. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D, Ghomashchi F, Yates JR 3rd, Armstrong CG, Paterson A, Cohen P, Fukunaga R, Hunter T, Kudo I, Watson SP, Gelb MH. Serine 727 phosphorylation and activation of cytosolic phospholipase A₂ by MNK1-related protein kinases. *J. Biol. Chem* 2000;275:37542–37551. [PubMed: 10978317]
81. Das S, Rafter JD, Kim KP, Gygi SP, Cho W. Mechanism of group IVA cytosolic phospholipase A₂ activation by phosphorylation. *J. Biol. Chem* 2003;278:41431–41442. [PubMed: 12885780]
82. Evans JH, Fergus DJ, Leslie CC. Inhibition of the MEK1/ERK pathway reduces arachidonic acid release independently of cPLA₂ phosphorylation and translocation. *BMC Biochemistry* 2002;3:30. [Computer File]. [PubMed: 12370087]
83. Dessen A, Tang J, Schmidt H, Stahl M, Clark JD, Seehra J, Somers WS. Crystal structure of human cytosolic phospholipase A₂ reveals a novel topology and catalytic mechanism. *Cell* 1999;97:349–360. [PubMed: 10319815]
84. Börsch-Haubold AG, Bartoli F, Asselin J, Dudler T, Kramer RM, Apitz-Castro R, Watson SP, Gelb MH. Identification of the phosphorylation sites of cytosolic phospholipase A₂ in agonist-stimulated human platelets and HeLa cells. *J. Biol. Chem* 1998;273:4449–4458. [PubMed: 9468497]
85. de Carvalho MGS, McCormack AL, Olson E, Ghomashchi F, Gelb MH, Yates JR III, Leslie CC. Identification of phosphorylation sites of human 85-kDa cytosolic phospholipase A₂ expressed in insect cells and present in human monocytes. *J. Biol. Chem* 1996;271:6987–6997. [PubMed: 8636128]
86. Tian W, Wijewickrama GT, Kim JH, Das S, Tun MP, Gokhale N, Jung JW, Kim KP, Cho W. Mechanism of regulation of Group IVA phospholipase A₂ activity by Ser727 phosphorylation. *J. Biol. Chem* 2008;283:3960–3971. [PubMed: 18065419]
87. Yao X-L, Cowan MJ, Gladwin MT, Lawrence MM, Angus CW, Shelhamer JH. Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A₂ activity. *J. Biol. Chem* 1999;274:17202–17208. [PubMed: 10358078]
88. Wu T, Angus CW, Yao X-L, Logun C, Shelhamer JH. p11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDa cytosolic phospholipase A₂. *J. Biol. Chem* 1997;272:17145–17153. [PubMed: 9202034]
89. Das S, Cho W. Roles of catalytic domain residues in interfacial binding and activation of group IV cytosolic phospholipase A₂. *J. Biol. Chem* 2002;277:23838–23846. [PubMed: 11956215]
90. Leslie CC, Channon JY. Anionic phospholipids stimulate an arachidonoyl-hydrolyzing phospholipase A₂ from macrophages and reduce the calcium requirement for activity. *Biochim. Biophys. Acta* 1990;1045:261–270. [PubMed: 2167132]
91. Six DA, Dennis EA. Essential Ca²⁺-independent role of the group IVA cytosolic phospholipase A₂ C2 domain for interfacial activity. *J. Biol. Chem* 2003;278:23842–23850. [PubMed: 12672805]
92. Casas J, Gijón MA, Vigo AG, Sanchez Crespo M, Balsince J, Balboa MA. Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A₂ to perinuclear membranes and decreases its calcium requirement for translocation in live cells. *Mol. Biol. Cell* 2006;17:155–162. [PubMed: 16221889]
93. Choukroun GJ, Marshansky V, Gustafson CE, McKee M, Hajjar RJ, Rosenzweig A, Brown D, Bonventre JV. Cytosolic phospholipase A₂ regulates Golgi structure and modulates intracellular trafficking of membrane proteins. *J. Clin. Invest* 2000;106:983–993. [PubMed: 11032858]
94. Grimmer S, Ying M, Walchli S, van Deurs B, Sandvig K. Golgi vesiculation induced by cholesterol occurs by a dynamin- and cPLA₂-dependent mechanism. *Traffic* 2005;6:144–156. [PubMed: 15634214]

95. Cubells L, Vila de Muga S, Tebar F, Bonventre JC, Balsinde J, Pol A, Grewal T, Enrich C. Annexin A6-induced inhibition of cytoplasmic phospholipase A₂ is linked to caveolin-1 export from the Golgi. *J. Biol. Chem* 2008;283:10174–10183. [PubMed: 18245088]
96. Yang J-S, Gad H, Lee SY, Mironov AA, Zhang L, Beznoussenko GV, Valente C, Tracchio G, Bonsra AN, Du G, Baldanzi G, Graziani A, Bouroin S, Frohman MA, Luini A, Hsu VW. A role for phosphatidic acid in COPI vesicle fission yields insights into Golgi maintenance. *Nature Cell Biol* 2008;10:1146–1153. [PubMed: 18776900]
97. Morikawa RK, Aoki J, Kano F, Murata M, Yamamoto A, Tsujimoto M, Arai H. Intracellular phospholipase A₁γ (iPLA₁γ) is a novel factor involved in coat protein complex I- and Rab6-independent retrograde transport between the endoplasmic reticulum and the Golgi complex. *J. Biol. Chem* 2009;284:26620–26630. [PubMed: 19632984]
98. Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. *Biochim. Biophys. Acta* 2008;1778:794–809. [PubMed: 17961505]
99. Herbert SP, Ponnambalam S, Walker JH. Cytosolic phospholipase A₂-α mediates endothelial cell proliferation and is inactivated by association with the Golgi apparatus. *Mol. Biol. Cell* 2005;16:3800–3809. [PubMed: 15930125]
100. Whately RE, Satoh K, Zimmerman GA, McIntyre TM, Prescott SM. Proliferation-dependent changes in release of arachidonic acid from endothelial cells. *J. Clin. Invest* 1994;94:1889–1900. [PubMed: 7962534]
101. Herbert SP, Odell AF, Ponnambalam S, Walker JH. The confluence-dependent interaction of cytosolic phospholipase A₂-α with annexin A1 regulates endothelial cell prostaglandin E₂ generation. *J. Biol. Chem* 2007;282:34468–34478. [PubMed: 17873281]
102. Regan-Klapisz E, Krouwer V, Langelaar-Makkinje M, Nallan L, Gelb M, Gerritsen H, Verkleij AJ, Post JA. Golgi-associated cPLA₂α regulates endothelial cell-cell junction integrity by controlling the trafficking of transmembrane junction proteins. *Mol. Biol. Cell* 2009;20:4225–4234. [PubMed: 19675210]
103. Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F, Matsuura T, Wada M, Fujii Y, Yamada M, Ogawa T, Okada T, Hashizume H, Kii M, Hara S, Hagishita S, Nakamoto S, Yamada K, Chikazawa Y, Ueno M, Teshirogi I, Ono T, Ohtani M. Pyrrolidine inhibitors of human cytosolic phospholipase A₂. *J. Med. Chem* 2000;43:1041–1044. [PubMed: 10737736]
104. Lee KL, Foley MA, Chen L, Behnke ML, Lovering FE, Kirincich SJ, Wang W, Shim J, Tam S, Shen MWH, Khor SP, Xu X, Goodwin DG, Ramarao MK, Nickerson-Nutter C, Donahue F, Ku MS, Clark JD, McKew JC. Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A₂α. *J. Med. Chem* 2007;50:1380–1400. [PubMed: 17305324]
105. Ghomashchi F, Stewart A, Hefner Y, Ramanadham S, Turk J, Leslie CC, Gelb MH. A pyrrolidine-based specific inhibitor of cytosolic phospholipase A₂α blocks arachidonic acid release in a variety of mammalian cells. *Biochim. Biophys. Acta* 2001;1513:160–166. [PubMed: 11470087]
106. Mounier CM, Ghomashchi F, Lindsay MR, James S, Singer AG, Parton RG, Gelb MH. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A₂ occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A₂-α. *J. Biol. Chem* 2004;279:25024–25038. [PubMed: 15007070]
107. Ono T, Yamada K, Chikazawa Y, Ueno M, Nakamoto S, Okuno T, Seno K. Characterization of a novel inhibitor of cytosolic phospholipase A₂α, pyrrophenone. *Biochem. J* 2002;363:727–735. [PubMed: 11964173]
108. Tai N, Kuwabara K, Kobayashi M, Yamada K, Ono T, Seno K, Gahara Y, Ishizaki J, Hori Y. Cytosolic phospholipase A₂ α inhibitor, pyrroxyphenone, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. *Inflamm. Res* 2009;59:53–62. [PubMed: 19655230]
109. Marusic S, Thakker P, Pelker JW, Stedman NL, Lee KL, McKew JC, Han L, Xu X, Wolf SF, Borey AJ, Cui J, Shen MW, Donahue F, Hassan-Zahrae M, Leach MW, Shimizu T, Clark JD. Blockade of cytosolic phospholipase A₂α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. *J. Neuroimmunol* 2008;204:29–37. [PubMed: 18829119]
110. McKew JC, Lee KL, Shen MW, Thakker P, Foley MA, Behnke ML, Hu B, Sum F-W, Tam S, Hu Y, Chen L, Kirincich SJ, Michalak R, Thomason J, Ipek M, Wu K, Wooder L, Ramarao MK, Murphy EA, Goodwin DG, Albert L, Xu X, Donahue F, Ku MS, Keith J, Nickerson-Nutter C,

Abraham WM, Williams C, Hegen M, Clark JD. Indole cytosolic phospholipase A₂ α inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5Chloro-2-(2-{[3,4-dichlorobenzyl) sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic Acid, Efipladib. *J. Med. Chem* 2008;51:3388–3413. [PubMed: 18498150]

111. Ghosh M, Loper R, Ghomashchi F, Tucker DE, Bonventre JV, Gelb MH, Leslie CC. Function, activity and membrane targeting of cytosolic phospholipase A₂ ζ in mouse lung fibroblasts. *J. Biol. Chem* 2007;282:11676–11686. [PubMed: 17293613]
112. Ludwig J, Bovens S, Brauch C, Elfringhoff AS, Lehr M. Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A₂ α . *J. Med. Chem* 2006;49:2611–2620. [PubMed: 16610804]
113. Kokotos G, Kotsovolou S, Six DA, Constantinou-Kokotou V, Beltzner CC, Dennis EA. Novel 2-oxoamide inhibitors of human group IVA phospholipase A₂. *J. Med. Chem* 2002;45:2891–2893. [PubMed: 12086476]




Fig. 1. Proposed mechanism of cPLA₂α localization and function on the Golgi

The N-terminal C2 domain of cPLA₂α is attached to a large catalytic domain that contains the catalytic site Ser/Asp dyad, and the sites phosphorylated by MAPKs (Ser505) and MAPK-interacting kinases (Ser727). The hydroxyl group of Ser727 interacts with p11/Annexin A2 complexes maintaining cPLA₂α in an inactive state. Phosphorylation of Ser727 causes disassociation of the bulky p11/Annexin A2 complex allowing the calcium-dependent interaction of cPLA₂α with the Golgi membrane. Calcium binding to the cPLA₂α C2 domain reduces the negative electrostatic potential of the surface exposed CBLs allowing the surrounding hydrophobic residues (green) in CBL1 and CBL3 to penetrate the membrane. The basic residues (R57/K58/R59) (yellow) in the C2 domain of cPLA₂α form the proposed site for interaction with C-1-P. Calcium-dependent binding of cPLA₂α to the Golgi positions the catalytic domain on the membrane, which is stabilized by interaction of Trp464 (red) in the catalytic domain with the membrane. There is evidence that association of cPLA₂α with the Golgi is influenced by changes in cholesterol content. Phosphorylation at Ser505 increases the hydrolytic activity of cPLA₂α on the membrane perhaps by promoting a conformational change due to its proximity to the flexible linker that connects the catalytic and C2 domains. A patch of basic residues (K488/K541/K543/K544) (teal) in the catalytic domain also regulates the ability of cPLA₂α to release arachidonic acid from the Golgi. These residues are necessary for activation of cPLA₂α *in vitro* by polyphosphoinositides, however, the endogenous anionic components in the Golgi that interact with this basic site have not been identified. Therefore

the ability of cPLA₂ α to release arachidonic acid (AA) and form lysophospholipids in the Golgi involves increases in calcium, phosphorylation and interaction of basic residues with anionic components in the membrane. Lysophospholipids generated at the rims of the Golgi cisternae by cPLA₂ α are thought to induce positive membrane curvature for formation of tubules that connect the Golgi stacks and promote intra-Golgi transport. Surface representation of the x-ray crystal structure of cPLA₂ α (PDB: 1CJY) was made using PYMOL.